Last reviewed · How we verify
Bifidobacteri
Bifidobacteri, marketed by RenJi Hospital, is a microbiome-based therapeutic currently available in the market. The key composition patent for Bifidobacteri is set to expire in 2028, providing a period of exclusivity that could maintain its market position. The primary risk is the potential entry of generic competitors post-patent expiry, which may erode market share and revenue.
At a glance
| Generic name | Bifidobacteri |
|---|---|
| Also known as | Live Combined Bifidobacterium，Lactobac and Enterococcus Capsules, (produced by Shanghai XinYi Company) |
| Sponsor | RenJi Hospital |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |